Foghorn Therapeutics vs Verrica Pharmaceuticals
Verrica Pharmaceuticals reported revenue of $36 million in fiscal 2025, 1.2 times Foghorn Therapeutics' $31 million in fiscal 2025. Foghorn Therapeutics' revenue grew 36.8% in its latest year, and Verrica Pharmaceuticals' grew 370.2%. Foghorn Therapeutics had an operating margin of -279.5%, against -34.2% at Verrica Pharmaceuticals. Free cash flow was −$86 million at Foghorn Therapeutics and −$18 million at Verrica Pharmaceuticals.
Side by side
| Foghorn Therapeutics | Verrica Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $31M | $36M |
| Revenue growth | 36.8% | 370.2% |
| Revenue growth a year, last 5 years | 138.6% | — |
| Gross margin | — | — |
| Operating margin | −279.5% | −34.2% |
| Net margin | −240.3% | −50.3% |
| Free cash flow | −$86M | −$18M |
| Free cash flow margin | −278.7% | −49.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 14.7% | 105.6% |
| Last close | $1.78 | $2.88 |
| P/E at the last close | 25.4× | — |
| Insider trades, last 12 months | — | bought $18.2 million, sold $0 |
| Piotroski F-score | 2 of 8 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Foghorn TherapeuticsVerrica Pharmaceuticals
Operating margin
Percent of revenue
Foghorn TherapeuticsVerrica Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Foghorn TherapeuticsVerrica Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Foghorn Therapeutics and Verrica Pharmaceuticals pages.